This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

EfficacyEfficacyEfficacyKey HighlightsSafetySafetySafetySelected Adverse EventsDosingDosingDosingAdditional Administration informationSupport & resourcesSupport & resourcesResource overviewPatient SupportGuidelinesELN 2022 GuidelinesKey topics in AML video seriesEfficacy and Safety videoPubExplainer videos

Patient Fitness in AML

The content of this website has been produced in line with the MYLOTARG® (gemtuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. For  MYLOTARG® (gemtuzumab ozogamicin) and cytarabine Prescribing Information Click here. Adverse event reporting information can be found at the bottom of the page.

PubExplainer videos

Three animated videos which explain in a clear and succinct way:​​​​​​​

1. Mechanism of action and the fractionated dosing schedule for MYLOTARG2. The key data from the Phase III ALFA-0701 study3. Measurable residual disease (MRD) and why it mattersMechanism of action and the Fractionated dosing schedule for MYLOTARG

A short video (3.03 duration) explaining

-MYLOTARG's mechanism of action

-Leading to the rationale of MYLOTARG's fractionated dosing schedule

-The resulting efficacy and safety data from the ALFA-0701 study

-Summary of the NICE recommendation

ALFA-0701 studyA quick video (03.26 duration) that covers all the key points related to the pivotal Phase III ALFA-0701 study

- Study Design

- Baseline characteristics- Induction and Consolidation courses- Primary endpoint: Event Free survival results by cytogenetic group- Secondary endpoint: Relapse Free Survival results- Adverse Events reported
What is MRD and why does it matter?

This video (3.33 duration) aims to illustrate the concept of MRD by aggregating findings from different disease areas, studies and results. Its main focus is on Acute Lymphoblastic Leukaemia and data on  Acute Myeloid Leukaemia is shown at time point 2.40.

This video covers:-Definition of MRD-Detection-Principles
-Relevance: Complete remission-Impact on Survival rates and patient outcomes

AML, Acute Myeloid Leukaemia; MRD, measurable residual disease

PP-MYL-GBR-0689. April 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​